Document Type

Conference Proceeding

Publication Date

1-8-2025

Publication Title

American Journal of Health-System Pharmacy

Abstract

Purpose: As of January 2024, Corewell Health East hospitals updated their guidelines to include tenecteplase as the first line agent in the treatment of acute ischemic stroke. Tenecteplase is a high-risk medication, it is important to identify opportunities to improve its use and patient safety. This study aims to evaluate the appropriate usage and hemorrhagic events of tenecteplase in patients with suspected acute ischemic stroke according to Corewell Health Beaumont Troy Hospital guidelines. Methods: This was a single-center retrospective cohort study that evaluated adults age 18 years and older admitted to Corewell Health Beaumont Troy Hospital for acute ischemic stroke between January 9, 2024, and June 30, 2024. Patients were excluded if they received tenecteplase for any other indication besides acute ischemic stroke or received an alternative thrombolytic agent for the treatment of acute ischemic stroke. Patient information was collected through the hospital’s electronic medical record and verified with local medication delivery log. The primary outcome of the study was the number of patients who received tenecteplase for acute ischemic stroke in accordance with institutional guidelines. Secondary outcomes included the time from stroke symptom onset to time of tenecteplase administration, stroke severity before and after tenecteplase was administered, blood pressure management strategies required, the number and significance of any bleeding events, and the patient disposition at discharge.

Volume

82

Issue

Suppl 1

First Page

S929

Last Page

S929

Comments

2024 ASHP (American Society of Health-System Pharmacists) Midyear Clinical Meeting, December 8-12, 2024, New Orleans, LA

DOI

10.1093/ajhp/zxae345

Download

Share

COinS